Press Releases Items Per Page 102550 Year None2021202020192018201720162015201420132012201120102007 11.04.20 Syndax Pharmaceuticals to Present Updated Data from Phase 1 Trial of Axatilimab in cGVHD During Oral Session at the 62nd ASH Annual Meeting 11.02.20 Syndax Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Business Update 10.26.20 Syndax to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 2, 2020 09.02.20 Syndax Announces Participation at Three Upcoming Investor Conferences 08.06.20 Syndax Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update 08.03.20 Syndax Announces Participation in BTIG Virtual Biotechnology Conference 07.30.20 Syndax to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 6, 2020 07.07.20 Syndax Pharmaceuticals Appoints Daphne Karydas as Chief Financial Officer 05.21.20 ECOG-ACRIN Provides Syndax Pharmaceuticals With Results of Phase 3 E2112 Trial of Entinostat Plus Exemestane in Patients with HR+, HER2- Breast Cancer 05.12.20 Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 05.07.20 Syndax Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Clinical and Business Update 04.30.20 Syndax Announces Pricing of Public Offering of Common Stock Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
11.04.20 Syndax Pharmaceuticals to Present Updated Data from Phase 1 Trial of Axatilimab in cGVHD During Oral Session at the 62nd ASH Annual Meeting
11.02.20 Syndax Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Business Update
10.26.20 Syndax to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 2, 2020
08.06.20 Syndax Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update
07.30.20 Syndax to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 6, 2020
05.21.20 ECOG-ACRIN Provides Syndax Pharmaceuticals With Results of Phase 3 E2112 Trial of Entinostat Plus Exemestane in Patients with HR+, HER2- Breast Cancer
05.12.20 Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
05.07.20 Syndax Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Clinical and Business Update
